67,676 Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) by 18.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 295,844 shares of the company’s stock after selling 67,676 shares during the quarter. Fisher Asset Management LLC’s holdings in Monte Rosa Therapeutics were worth $3,529,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Allworth Financial LP purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at $30,000. Sterling Capital Management LLC raised its position in shares of Monte Rosa Therapeutics by 842.3% in the 3rd quarter. Sterling Capital Management LLC now owns 2,450 shares of the company’s stock worth $29,000 after buying an additional 2,190 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of Monte Rosa Therapeutics in the 3rd quarter worth $48,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Monte Rosa Therapeutics in the 3rd quarter worth $52,000. Finally, E Fund Management Co. Ltd. acquired a new position in Monte Rosa Therapeutics in the second quarter valued at $200,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GLUE shares. HC Wainwright started coverage on Monte Rosa Therapeutics in a report on Thursday, October 1st. They issued a “buy” rating and a $25.00 target price on the stock. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Wall Street Zen upgraded Monte Rosa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Benchmark restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, October 5th. Finally, JPMorgan Chase & Co. reduced their price objective on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.44.

Check Out Our Latest Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Stock Down 2.2%

NASDAQ GLUE opened at $9.16 on Tuesday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $8.95 and a fifty-two week high of $25.77. The business has a 50 day moving average price of $11.21 and a two-hundred day moving average price of $16.70. The stock has a market cap of $782.72 million, a PE ratio of -6.54 and a beta of 1.40.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.24. The company had revenue of $54.37 million during the quarter, compared to analysts’ expectations of $33.87 million. Monte Rosa Therapeutics had a negative net margin of 186.24% and a negative return on equity of 30.14%. Sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Monte Rosa Therapeutics Company Profile

(Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

Read More

Want to see what other hedge funds are holding GLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report).

Institutional Ownership by Quarter for Monte Rosa Therapeutics (NASDAQ:GLUE)

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.